# REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 YTD Q3 Statement of Cash Flows

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: 2024-01-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-10-31, accession number 0001804220-24-000040
- Page: https://plicit.ai/financials/regn/fy2024-ytd-q3-cash-flow
- Chart image: https://plicit.ai/charts/regn-fy2024-ytd-q3-cash-flow-sankey.png

## Chart details

Cash flows for Jan 1, 2024 through Sep 30, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Sep 30, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

- **Beginning cash on Dec 31, 2023**: 2,737,800,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- **Operating activities**: 3,157,700,000 US dollars. Net cash provided.
- **Net income**: 3,494,900,000 US dollars
- **Increase in accounts payable, accrued expenses, and other liabilities**: 509,500,000 US dollars
- **Increase in prepaid expenses and other assets**: negative 352,200,000 US dollars
- **Other non-cash items, net**: negative 31,900,000 US dollars
- **Stock-based compensation expense**: 678,400,000 US dollars
- **(Gains) losses on marketable and other securities, net**: negative 331,200,000 US dollars
- **Increase in accounts receivable**: negative 436,200,000 US dollars
- **Increase in inventories**: negative 502,000,000 US dollars
- **Depreciation and amortization**: 356,500,000 US dollars
- **Deferred income taxes**: negative 477,100,000 US dollars
- **Increase (decrease) in deferred revenue**: 249,000,000 US dollars
- **Investing activities**: negative 2,818,700,000 US dollars. Net cash used.
- **Purchases of marketable and other securities**: negative 14,664,500,000 US dollars
- **Acquisitions, net of cash acquired**: negative 5,000,000 US dollars
- **Payments for Libtayo intangible asset**: negative 58,300,000 US dollars
- **Capital expenditures**: negative 556,300,000 US dollars
- **Sales or maturities of marketable and other securities**: 12,445,300,000 US dollars
- **Proceeds from sale of property, plant, and equipment**: 20,100,000 US dollars
- **Financing activities**: negative 1,065,000,000 US dollars. Net cash used.
- **Proceeds from issuance of Common Stock**: 1,374,400,000 US dollars
- **Payments in connection with Common Stock tendered for employee tax obligations**: negative 775,700,000 US dollars
- **Other**: negative 33,400,000 US dollars
- **Repurchases of Common Stock**: negative 1,630,300,000 US dollars
- **Operating adjustment reconciliation**: 2,130,600,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- **financing gross reconciliation**: 2,439,400,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **investing gross reconciliation**: 15,284,100,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **Exchange-rate effect**: 0 US dollars
- **Ending cash on Sep 30, 2024**: 2,011,800,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- **Cash sources and uses**: 5,895,500,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- **Net cash change**: negative 726,000,000 US dollars. Ending cash minus beginning cash.
- **Cash flow / Net income**: 0.90×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
- **Operating cash flow**: 3,157,700,000 US dollars. Operating cash flow used in the free cash flow calculation.
- **cash spent on productive assets**: 556,300,000 US dollars. These cash purchases are already included in investing activities above.
- **Free cash flow**: 2,601,400,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

### Chart connections

- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net income exceeds operating cash. The diagram allocates $3.16B of net income directly to operating cash and $337.20M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash spent on productive assets equals free cash flow: 3,157,700,000 US dollars minus 556,300,000 US dollars equals 2,601,400,000 US dollars.